DYRK1A and cancer: All the isolated compounds were tested against the bacteria Staphylococcus aureus and Escherichia coli as well as against eight different protein kinases relevant to cell proliferation, cancer, diabetes, and neurodegenerative disorders (CDK1, CDK2, CDK5, CDK9, CK1, CLK1, DYRK1A, and GSK3) and in both amyloid β-42 assays (amyloid β-42 induction assay and inhibition of amyloid β-42 production induced by aftin-5 assay).